We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AAN

News List

ATH434 protects brain cells and improves motor function in Parkinsonian disorder prnasia
April 22, 2021
Alterity Therapeutics announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) ...
AAN Issues Guideline on Vaccines and MS americanpharmaceuticalreview
September 03, 2019
According to guidelines developed by the American Academy of Neurology (AAN), people with MS should receive recommended vaccinations, including yearly flu shots.
AveXis Presented Robust Data at AAN Demonstrating Efficacy of Zolgensma in Broad Spectrum of Spinal Muscular Atrophy (SMA) Patients drugs
May 08, 2019
AveXis, a Novartis company, today announced interim data from ongoing trials of the investigational product Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101)1 that showed positive results across a broad spectrum of patients with spinal muscular atrophy